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single pill anti-hypertensive combination therapies in a tertiary 
healthcare facility in Nigeria. 
METHODS
Patients 
Three hundred and seventy three (373) hypertensive parti-
cipants aged 18-years and above and presenting de novo to 
the Cardiology Unit of University of Abuja Teaching Hospital 
during a 1-year period (2016 - 2017) were studied. Patients 
were referred from both primary and secondary health centres 
INTRODUCTION
It has been shown that as low as 2mmHg reduction in systolic 
blood pressure (BP) is associated with a 7% reduction in the 
risk of ischaemic heart disease and a 10% reduction in the risk 
of stroke.(1) In addition, numerous large clinical trials have 
demonstrated that most patients require more than one anti- 
hypertensive agent to achieve target BP.(2-4) Therefore, current 
guidelines,(5-11) recommend the use of combination therapy as 
first-line treatment or early in the management of hypertensive 
patients. Furthermore, with the benefits of single pill anti-
hypertension combination therapy, contemporary guidelines on 
the management of hypertension now favour their use.(5-9)
Whereas the benefits of combination therapy including single 
pill combinations are obvious, and the best combination for 
the black African hypertensive patient has been described,(12) 
there is a lack of data on the frequency of the use of single pill 
anti-hypertensive combination therapies in health facilities. We 
therefore aim to study the frequency, and pattern of use of 
ABSTRACT
Background: Majority of patients with hypertension 
require 2 or more medications to provide adequate 
blood pressure (BP) control. In addition, contemporary 
guidelines on the management of hypertension favor 
the use of single-pill combinations (SPCs) as they sim-
plify the treatment regimen and decrease the daily pill 
burden for patients, both of which are associated with 
improved adherence. In spite of this, there is a lack of 
data in sub-Saharan Africa on the frequency of use of 
SPC anti-hypertensive medications. 
Method: We prospectively collected detailed clinical 
data from 373 patients with primary diagnosis of hyper-
tension attending the cardiology clinic of University of 
Abuja Teaching Hospital between 2016 and 2017.
Results: Three hundred and seventy three patients with 
mean age of 50.6 ± 12.3 years and mean body mass 
index of 31.2 ± 6.5kg/m2 on anti-hypertensive treat-
ment were evaluated. Baseline mean systolic and dias-
tolic BPs were 161.1 ± 3.1mmHg and 95.4 ± 15.6mmHg 
respectively, while the mean pulse pressure was 56.6 ± 
18.1mmHg. 212 (56.8%) where on SPCs, with 32.5% on 
angiotensin receptor blockers (ARBs) plus hydro-
chlorothiazide (HCTZ), 18.9% on angiotensin convert-
ing enzyme inhibitors (ACEIs) plus HCTZ, 9.9% on 
amlodipine (AML) plus ARB, 3.3% on AML plus ACEI, 
3.8% on thiazide-like diuretic plus atenolol, 29.2% on 
HCTZ plus amiloride, and 2.4% on triple combination of 
AML+ARB+HCTZ. 
Conclusion: Our study has shown that over 50% of our 
patients were on SPC anti-hypertensive medications, 
with the most prescribed single pill combination being 
angiotensin receptor blocker plus thiazide diuretic.
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in neighbouring towns and states. Reasons for referral ranged 
from poor blood pressure control to suspected target organ 
damage, especially left atrial enlargement and left ventricular 
hypertrophy, as detected by electrocardiography. Patients were 
captured as part of the Abuja Heart Registry which was a 
prospective registry of all patients presenting to the Cardiology 
Unit of University of Abuja Teaching Hospital from April 2006 - 
April 2017.(11)
Measurements
Baseline clinical and demographic characteristics were obtained 
from the patients using case report forms. Information obtained 
were age, sex and type of anti-hypertensive medications. 
Patients’ height was measured with patients wearing no shoes 
or headgear. Body mass index was calculated using the formula 
weight/height2. Blood pressure measurements were obtained 
according to standard guidelines with a mercury sphygmo-
manometer (Accouson, London). Systolic and diastolic BPs 
were measured at Korotkoff sounds I and V, respectively. BP 
was measured from the right arm 3 times after a 5-minute rest 
with the patient in a sitting position, and the average of the 3 
measurements was obtained. Each patient had fasting blood 
sugar, fasting lipid profile, electrolyte, urea and creatinine, and 
full blood cell count assessed after an 8- to 12-hour fast. All 
patients gave written informed consent before they were 
enrolled into the study. Ethical clearance was obtained from 
University of Abuja Teaching Hospital Ethical Clearance 
Committee.
STATISTICAL ANALYSIS
SPSS software version 20.0 (SPSS Inc., Chicago, IL) was used for 
statistical analysis. Continuous variables were expressed as 
mean ± SD and categorical variables expressed as percentages. 
Comparison of baseline characteristics in male and female 
patients was performed by Student’s t-test. A 2-tailed p-value 
<0.05 was considered to be significant. 
RESULTS
Table 1 shows the clinical and demographic characteristics of 
the study population with 47.5% being female. The patients 
were on average middle-aged (51.6 ± 11.6 years), and there 
was no age difference between the male and female population. 
There was also no difference in blood pressure and metabolic 
profiles between the male and female patients. The female 
patients however had signif icantly higher body mass index 
compared to the male patients (31.9 ± 7.4kg/m2 versus 28.1 ± 
5.3kg/m2, p<0.001).
Figure 1 shows the pattern of prescription of SPC anti-hyper-
tensive medications. 56.8% of the 373 patients studied were 
on SPCs. The most prescribed SPC is ARB plus HCTZ in 32.5% 
of cases, while HCTZ plus amiloride was the second most 
prescribed combination in 29.2% of cases. The least prescribed 
2-drug SPC anti-hypertensive medication is AML plus ARB in 
3.3% of cases, while the least prescribed is the triple pill 
combination of AML plus ARB plus HCTZ in 2.4% of cases.
TABLE I: Baseline characteristics of the study population.
Variable All Patients (n = 373) Male patients
High
≥11mmol/l
n = 998 (35%)
p-value
Age, years 51.6  ±  11.6 51.9 ± 11.4 51.1 ± 11.9 0.49
BMI, kg/m2 29.9 ± 6.7 28.1 ± 5.3 31.9 ± 7.4 <0.001
SBP, mmHg 155.1 ± 24.7 154.8 ± 24.9 155.7 ± 24.6 0.63
DBP, mmHg 95.5 ± 15.0 94.9 ± 14.6 96.2 ± 15.5 0.41
FBS, mmol/l 5.8 ± 2.6 5.6 ± 2.0 6.0 ± 3.1 0.25
Total Cholesterol, mmol/l 5.1 ± 1.2 4.9 ± 0.53 5.2 ± 1.3 0.08
Triglyceride, mmol/l 1.4 ± 0.6 1.4 ± 0.7 1.4 ± 0.7 0.42
LDL Cholesterol, mmol/l 3.1 ± 1.1 3.0 ± 1.0 3.2 ± 1.1 0.39
HDL Cholesterol, mmol/l 1.4 ± 0.4 1.3 ± 0.39 1.4  ±  0.5 0.06
PCV, % 38.5 ± 5.3 38.5 ± 6.2 38.6 ± 4.7 0.94
WBC 6.2 ± 2.8 6.7 ± 1.2 5.7 ± 2.0 0.24
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, FBS = Fasting Blood Sugar, HDL = High Density Lipoprotein, LDL = Low Density Lipoprotein, PCV =Packed Cell Volume, 




Our study has shown that 56.8% of the 373 hypertensive 
patients studied received one form of SPC or the other with 
the most prescribed single pill combination being angiotensin 
receptor blocker plus thiazide diuretic. The proportion of 
56.8% of our patients receiving SPC anti-hypertensive medica-
tions is much higher than the proportion of 20.0% recently 
reported in a study in Japan.(13) The higher rate of single pill 
prescription in our study compared to that in Japan might be 
attributed to the fact that our study was in a specialist cardiology 
clinic while the study in Japan was in both general and specialty 
clinics. It is well known that specialty physicians like cardiolo-
gists have a higher propensity of prescribing single pill anti-
hypertensive combination medications compared to general 
physicians.(14) The proportion of 56.8% in our study is higher 
than the proportion of 17.3% recorded in the same cardiology 
clinic in 2013. Therefore, there has been much improvement in 
the prescription of single pill anti-hypertensive combination 
medications in our clinic over the years. This increase can likely 
be attributed to increased availability of SPC anti-hypertensive 
medications in Nigeria and increased awareness of our physi-
cians on the advantages of SPC anti-hypertensive medications. 
Combination of ARB and HCTZ was the most prescribed SPC, 
with combination of telmisartan and HCTZ being the most 
used in this regard. There was a higher tendency to prescribe 
ARBS plus HCTZ over ACEIs plus HCTZ, and AML plus ACIS 
or ARBS. A higher tendency for ARBS and HCTZ to be pre-
scribed above combination of ACEIs plus HCTZ is most likely 
due to the better side effect profile of the former. It is well 
known that ACEI causes dry cough and angioedema and these 
side effects occur more in black patients compared to Caucasian 
population.(15) On the other hand, the higher prescription of 
ARBS plus HCTZ over combination of AML plus ARBS is most 
likely due to better availability and lower cost of the former. 
HCTZ and amiloride were the second most commonly pre-
scribed SPC in our study. A similar combination (HCTZ plus 
triamterene) was one of the most prescribed SPC in a study in 
the United States of America over a decade ago.(16) The choice 
of this combination over more contemporary combination 
therapies is likely due to its relatively lower cost compared to 
the other more conventional and reduction of hypokalaemia 
caused by HCTZ monotherapy. In the CREOLE study,(2) 
hypokalaemia was reported in over 5.3% of the patients who 
were on the combination of AML plus HCTZ even though this 
was the most efficacious of the 3 treatment arms in reducing 
BP. To mitigate this effect of hypokalemia, the triple combina-
tion of amlodipine, hydrochlorothiazide and amiloride could be 
a good option to be considered in the black population.
SPC of 3 medications of AML plus valsartan plus HCTZ was 
prescribed in 2.4% of the cases. With the burden of hyperten-
sion in the black population and difficult to treat blood pres-
sure in this population group,(7,18) the use of such single triple pill 
combination could significantly improve compliance and there-
fore BP control. 
In keeping with most current hypertension guidelines,(6-10) which 
discourage the combination of beta blockers and thiazide or 
thiazide-like diuretics because of increased metabolic side 
effects, the single pill combination of a beta blocker plus 
hydrochlorothiazide was prescribed in only 3.8% of the patients 
studied.
Similar to previous studies,(17) our female hypertensive patients 
had significantly higher body mass index and LDL cholesterol. 
The higher LDL cholesterol in female patients compared to 
male patients has been attributed to hormonal differences.(19) 
LIMITATIONS
Since this report applies strictly to a cardiology clinic, it is 
difficult to extrapolate this to the general anti-hypertensive 
prescription pattern in tertiary health facilities in Nigeria. 
ARB + HCT             ACEI + HCT             AML + ARB
AML + ACEI            Thiazide like + Atenolol
HCT + Potassium sparing diuretic               AML + ARB + HCT
FIGURE 1: Percentage distribution of the use of different 




















Our study has shown that more than half of hypertensive 
patients attending a cardiology clinic in a tertiary health facility 
in Nigeria were prescribed single pill anti-hypertensive medi-
cations. Although results of this study cannot be extrapolated 
to the general anti-hypertensive prescription pattern in tertiary 
health facilities in Nigeria, it is a pivot for future studies in this 
direction. It might also be necessary to see how single pill anti-
hypertensive medications affect blood pressure control when 
compared to individual medications in this population.
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